Ethyreal Bio, Inc. has made its official debut, launching with over $100 million in Series B investor-backed financing supporting its lead investigational program for thyroid eye disease (TED).
First, a rundown on Ethyreal.
Operating out of Cambridge, Massachusetts, the biotechnology company is primarily focused on developing precision therapies for thyroid diseases: Graves’ disease (GD) and thyroid eye disease (TED).
Its lead program: ETHY-001 (which we’ll get to in a moment).
And check out its leadership team.
Now to this financing.
The Series B financing ($101 million, to refresh) was led by Avoro Capital and included all healthcare investors who participated in the company’s Series A round:
- Atlas Venture
- Medicxi Venture
- Nandi Life Sciences
- Checkpoint Capital
Got it. Next up: this lead program.
The company’s primary focus is on ETHY-001, a monoclonal antibody.
Its purpose: To block autoantibody-mediated activation of the thyroid-stimulating hormone receptor (TSHR)—a shared pathogenic driver of both GD and TED.
A couple of notes:
- TSHR is a protein primarily located on thyroid cells; GD is thought to result from abnormal activities of pathogenic antibodies mediated through TSHR.
- Read up on its GD connection here.
- An estimated 50% of all GD patients eventually develop TED.
So how does this therapy target TSHR?
ETHY-001 is engineered to provide rapid onset and "robust efficacy” for both GD and TED by stimulating autoantibodies to precisely target TSHR, according to Ethyreal.
- These thyroid-stimulating autoantibodies (TSAbs) are responsible for targeting and activating TSHR
The thought, per the company:
- “In the orbit of the eye, this approach is expected to treat the signs and symptoms of TED”
- “In thyroid cells, this same approach is predicted to treat GD by reducing excess thyroid hormone production”
And its mechanism of action?
Infrequent, low-volume subcutaneous (SC) administration (with plans for via an autoinjector).
To note: The company has not specified the exact frequency (or lack thereof) for this injection; however, it did share that half-life extension technology will be incorporated into this treatment to enable the infrequent dosing.
Noted. Now, how does this compare to other TED treatments?
While the FDA has already approved Amgen’s TEPEZZA (teprotumamb-trbw)—the first (and currently only) treatment for TED—there is still:
- No therapy that addresses both GD and TED
- No therapy for GD that treats or prevents TED
- No medication that address the causal disease process of GD
Plus, circling back to that injection frequency component: TEPEZZA is administered as an intravenous (IV) injection in the arm every 3 weeks for 8 infusions.
- See here for recent phase 3 data evaluating a potential SC option
So … is there any clinical data on ETHY-001 yet?
Ethyrea has spoken on the potential of its therapeutic to “comprehensively halt disease activity,” as well as its safety profile in supporting “long-term and durable treatment control.
As for actual clinical data: The company recently presented preclinical findings during the Endocrine Society’s 2026 Annual Meeting (ENDO 2026) in Chicago, Illinois.
- At the time of this article’s publication, that data was not readily available—though we do know it will be presented by Ethyreal’s Kelly Foster, PhD, senior vice president, Translational Medicine, as well as its title:
- ETHY-001, a Half-Life Extended, TSHR Monoclonal Antibody Antagonist, Potently Inhibits TSHR Activation Induced by Patient Sera and M22-Induced Hyaluronan and IL-6 Secretion from TED Patient-Derived Orbital Fibroblasts.
How about non-preclinical data?
Thanks to this Series B financing, Ethyreal is moving forward with plans to initiate first-in-human (FIH) clinical trials (note the plural) later this year. The current timeframe: H2 2026.
No further details were shared … so stay tuned in the coming months for an update!
And in the meantime: Click here for a look at other recent TED pipeline news (including Viridian’s own asset seeking to become the first autoinjector treatment for the disease).